Hutchison China MediTech has initiated a phase II study of sulfatinib in second-line biliary tract cancer patients in China.
Sulfatinib is an oral, novel angio-immunokinase inhibitor that selectively targets vascular endothelial growth factor receptor, fibroblast growth factor receptor (“FGFR”) and colony-stimulating factor-1 receptor , three key tyrosine kinase receptors involved in tumor angiogenesis and immune evasion. The first drug dose was administered on 9 January. This phase II study is a multi-centre, single-arm, open-label study to evaluate the efficacy and safety of sulfatinib as a monotherapy in treating advanced or metastatic BTC patients who failed one prior systemic therapy. The primary endpoint is progression free survival at 16 weeks, with secondary endpoints including objective response rate, disease control rate , duration of response, PFS, overall survival and safety.
Chi-Med also announced that it has initiated a phase II study of a combination therapy using fruquintinib and Iressa in the first-line setting for patients with advanced or metastatic non-small cell lung cancer in China.
Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors. The first drug dose was administered on 9 January. This phase II combination therapy study is a multi-centre , single-arm, open-label study. The objectives are to evaluate the safety and tolerability as well as preliminary efficacy of the combination therapy in the first-line setting for advanced or metastatic non-squamous NSCLC patients with epidermal growth factor receptor (“EGFR”) activating mutations. Treatment will be continued until disease progression or intolerable toxicity occurs.
And Chi-Med says data from the ongoing phase I/II clinical trial of fruquintinib in combination with paclitaxel (Taxol) in second-line patients with advanced gastric cancer will be presented at the 2017 Gastrointestinal Cancers Symposium sponsored by the American Society of Clinical Oncology, being held in San Francisco, California from 19-21 January. Chi-Med completed a phase Ib dose finding study of fruquintinib in combination with paclitaxel, which established a combination regimen that was well tolerated, and continued to enroll patients in this trial to expand the data-set.
At 8:15am: (LON:HCM) Hutchison China Meditech Ltd share price was +10p at 2217.5p
Story provided by StockMarketWire.com